^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | iparomlimab/tuvonralimab (PSB205) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
325P - A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with or without bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR wild-type cohort
Published date:
11/28/2022
Excerpt:
Pts with systemic treatment naive, stage IIIB/C and stage IV NSCLC with WT EGFR were enrolled. In the run-in period, pts received QL1706 (5 mg/kg)+paclitaxel (175 mg/m2, squamous NSCLC cohort)/pemetrexed (500 mg/m2, non-squamous NSCLC cohort)+carboplatin....ORR was 58.6% (squamous NSCLC cohort: 70.6%; non-squamous NSCLC cohort: 41.7%). DCR was 93.1% (27/29). The ORR and DCR per iRECIST were 62.1% (18/29) and 96.6% (28/29). The median PFS (mPFS) was 6.97 months (95% CI: 4.107, -) and mPFS per iRECIST was 7.98 months (95% CI: 4.107, -). The median follow-up for OS was 9.17 months (IQR: 6.87, 10.51)....QL1706 plus platinum-based chemo was well tolerated and showed promising antitumor activity as first-line treatment for pts with advanced EGFR WT NSCLC.
Secondary therapy:
carboplatin + pemetrexed
Trial ID:
